Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3337486

Cc1cc(CNCCC(C)C)ccc1-c1cccc(C(N)=O)c1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
SHMT1 P34896 1/20 0.42
HDAC1 Q13547 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CA2 P00918 1/20 0.40
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
F3 P13726 1/20 0.38
PPARA Q07869 1/20 0.37
LRRK2 Q5S007 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1347921 0.93 OPRM1 (0.46) AKR1C3AKR1C2SHMT1HDAC1OPRM1
Trifluoroacetic Acid SCHEMBL3342436 0.87 HDAC1 (0.54) HDAC1OPRM1OPRD1OPRK1CA2
SCHEMBL13633142 0.84 OPRM1 (0.45) AKR1C3AKR1C2SHMT1HDAC1OPRM1
Hydrochloric Acid SCHEMBL4082867 0.83 CA2 (0.46) AKR1C3AKR1C2SHMT1HDAC1OPRM1
SCHEMBL4075641 0.81 OPRM1 (0.52) HDAC1OPRM1OPRD1OPRK1CA2
Trifluoroacetic Acid SCHEMBL3345691 0.81 HDAC1 (0.52) HDAC1OPRM1OPRD1OPRK1CA2
SCHEMBL1347863 0.81 OPRM1 (0.52) SHMT1HDAC1OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL4475141 0.80 OPRM1 (0.51) HDAC1OPRM1OPRD1OPRK1CA2
SCHEMBL4073644 0.79 OPRM1 (0.53) HDAC1OPRM1OPRD1OPRK1CA2
SCHEMBL1345547 0.79 HDAC1 (0.58) HDAC1OPRM1OPRD1OPRK1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 AKR1C3 2572/4885AKR1C2 1973/4885SHMT1 4648/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 AKR1C3 2428/4885AKR1C2 2353/4885SHMT1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.